Background: Immunogen design to generate protective neutralizing antibodies is a central effort in HIV vaccine development and critically dependent on T follicular helper (TFH) cells. However, very little is known about the peripheral counterpart of HIV-specific TFH cells and the protein-specific help they might provide.
Methods: Biomark Fluidigm gene expression profiles from HIV-specific IL-21+ and IFNγ+ CD4 T cells were analyzed from chronic, treatment-naïve HIV-infected individuals. Epitope specificity of peripheral TFH cells and Th1 cells was defined by Elispot. HIV-specific TFH cell lines were generated and their functionality and phenotype assessed by flow cytometry. Helper activity of Gag-and Env-specific TFH cells were tested in a CD4-B cell as well as CD4-CD8 T cell co-culture assay. HIV-specific TFH responses from ALVAC/AIDSVAX and DNA/Ad5 vaccine recipients were also compared.
Results: HIV-specific IL21+CD4 T cells showed significantly higher expression of genes associated with TFH cells compared to IFNγ+ or IL21+/IFNγ+ CD4 T cells including BCL6, cMaf and CXCR5. IL21+CD4 T cells most closely resembled TFH cells compared to any other phenotypic description of pTFH cells. Besides CXCR5+, HIV-specific pTFH cells predominantly expressed ICOS and PD1 but were CCR7-. The frequency of HIV-specific pTFH cells was low when compared to HIV-specific IFNγ+CD4 cells (p<0.0001). Interestingly, while HIV-specific IFNγ+CD4 T cells dominantly targeted epitopes in Gag, HIV-specific TFH cells equally recognized epitopes within Gag and Env (p=0.0009). Gag- and Env-specific TFH cells were able to provide help to HIV-specific CD8 T cells in vitro, characterized by Perforin/GrzB induction. In contrast, however, Gag-specific TFH cells preferentially induced maturation and proliferation of B cells, while Env-specific TFH cells predominantly drove Ig class switching. Further analysis revealed that Env-specific TFH cells also displayed features indicative of Th2 cells compared to Gag-specific TFH responses (p=0.0003). Lastly, we found that ALVAC/AIDSVAX vaccine recipients had significantly higher levels of HIV-specific pTFH cells but comparable levels of HIV-specific Th1 cells as DNA/Ad5 vaccine recipients.
Conclusions: Given the evidence presented here for the role that IL21+CD4 T cells appear to play in the maturation of vaccine evoked humoral immune responses, these findings have clear implications for HIV vaccine design.